Thanks @Patrick_Ryan. I'd typed a bit prematurely about the "OMOP data set" and am aware of the federal, private, and academic institutions have transformed their respective datasets using the OMOP CDM v4 (or v5).
To provide you the context of my question, if I'm a scientist and want to use real-world evidence from OHDSI partners' datasets, which (from the list you'd directed me to) is sourced primarily from EHR and claims data, along with other real-world data sources, such as patient surveys (Patients Like Me), mobile device data, and social networking data (Twitter), I would initially take a step back and assess whether all these heterogenous data sources contain info on the disease area I'm studying. Accordingly, my question would be, "Out of all the RWD sources out there publicly available, which ones provide data on incidence and prevalence of patients with ulcerative colitis ?" From a regulatory perspective, a scientist from the FDA could ask a "Out of all the RWD sources available publicly, which ones provide data on opioid use across the US?" If I were an RWE scientist, before conducting any analysis, I would cast a broad search for all data sources possible relevant to the clinical or regulatory question at hand.
September 2017, the Duke-Margolis Health Policy held a conference described a 'fit-for-purpose' approach for regulatory use of RWE:
Currently, Patients Like Me has tabulated a list of all medical conditions for which they have data on: https://www.patientslikeme.com/conditions I wonder if OHDSI can provide the same.